Teriparatide (Forteo)

DRUG3 trials

Sponsors

Oregon Health and Science University, M.D. Anderson Cancer Center, Pfenex, Inc

Conditions

HypocalcemiaOsteogenesis ImperfectaOsteoporosis

Phase 2

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

TerminatedNCT00623974

M.D. Anderson Cancer CenterHypocalcemia

Start: 2008-05-31End: 2010-06-30Updated: 2012-12-06

Phase 3

A Comparison of PF708 and Forteo in Osteoporosis Patients

CompletedNCT03002428

Pfenex, IncOsteoporosis

Start: 2016-12-31End: 2018-05-31Updated: 2018-05-23

Phase 4

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

CompletedNCT00131469

Oregon Health and Science UniversityOsteogenesis Imperfecta

Start: 2005-06-30End: 2011-01-31Updated: 2019-04-24

Related Papers

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

Journal of Clinical Investigation2014-01-26205 citations